1 |
Andersen, M.E. and Krewski, D. (2010) The vision of toxicity testing in the 21st century: moving from discussion to action. Toxicol. Sci., 117, 17-24.
DOI
|
2 |
Judson, R.S., Kavlock, R.J., Setzer, R.W., Hubal, E.A., Martin, M.T., Knudsen, T.B., Houck, K.A., Thomas, R.S., Wetmore, B.A. and Dix, D.J. (2011) Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol., 24, 451-462.
DOI
|
3 |
Knudsen, T.B., Houck, K.A., Sipes, N.S., Singh, A.V., Judson, R.S., Martin, M.T., Weissman, A., Kleinstreuer, N.C., Mortensen, H.M., Reif, D.M., Rabinowitz, J.R., Setzer, R.W., Richard, A.M., Dix, D.J. and Kavlock, R.J. (2011) Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology, 282, 1-15.
DOI
|
4 |
Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., Mount, D.R., Nichols, J.W., Russom, C.L., Schmieder, P.K., Serrrano, J.A., Tietge, J.E. and Villeneuve, D.L. (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem., 29, 730-741.
DOI
|
5 |
Clewell, H.J., Tan, Y.M., Campbell, J.L. and Andersen, M.E. (2008) Quantitative interpretation of human biomonitoring data. Toxicol. Appl. Pharmacol., 231, 122-133.
DOI
|
6 |
Yoon, M., Cambell, J.L., Andersen, M.E. and Clewell, H.J. (2012) Quantitative in vitro to in vivo extrapolation of cellbased toxicity assay results. Crit. Rev. Toxicol., 42, 633-652.
DOI
|
7 |
Clewell, H.J., Gentry, P.R., Covington, T.R., Sarangapani, R. and Teeguarden, J.G. (2004) Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci., 79, 381-393.
DOI
|
8 |
Saghir, S.A., Khan, S.A. and McCoy, A.T. (2012) Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. Crit. Rev. Toxicol., 42, 323-357.
DOI
|
9 |
Clewell, H.J., Teequarden, J., McBonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry R. and Shipp, A. (2002) Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol., 32, 329-389.
DOI
|
10 |
Clewell, H.J., Reddy, M.B., Lave, T. and Andersen, M.E. (2007) Physiologically Based Pharmacokinetic Modeling. Preclinical Development Handbook, John Wiley and Sons, Inc. pp. 1167-1227.
|
11 |
Phillips, M.B., Yoon, M.Y., Young, B. and Tan, Y.M. (2014) Analysis of biomarker utility using a PBPK/PD model for carbaryl. Front. Pharmacol., 5, 246.
|
12 |
Price, P.S., Schnelle, K.D., Cleveland, C.B., Bartels, M.J., Hinderliter, P.M., Timchalk, C. and Poet, T.S. (2011) Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. Regul. Toxicol. Pharmacol., 61, 23-31.
DOI
|
13 |
Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R. and Beliles, R.P. (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health, 13, 407-484.
DOI
|
14 |
Jamei, M., Marciniak, S., Edwards, D., Wragg, K., Feng, K., Barnett, A. and Rostami-Hodjegan, A. (2013) The simcyp population based simulator: architecture, implementation, and quality assurance. Silico Pharmacol., 1, 9.
DOI
|
15 |
Wu, H., Yoon, M.Y., Verner, M.A., Xue, J., Luo, M., Andersen, M.E., Longnecker, M.P. and Clewell, H.J. (2015) Can the observed association between serum perfluoroalkyl sub stances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? Environ. Int., 82, 61-68.
DOI
|
16 |
Price, P.S., Conolly, R.B., Chaisson, C.F., Gross, E.A., Young, J.S., Mathis, E.T. and Tedder, D.R. (2003) Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol., 33, 469-503.
DOI
|
17 |
Houston, J.B. and Galetin, A. (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab., 9, 940-951.
DOI
|
18 |
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. and Rostami-Hodjegan, A. (2009) The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol., 5, 211-223.
DOI
|
19 |
Rostami-Hodjegan, A. and Tucker, G.T. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discovery, 6, 140-148.
DOI
|
20 |
Clewell, H.J. and Andersen, M.E. (1996) Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology, 111, 315-329.
DOI
|
21 |
Clewell, H.J. (1993) Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol. Lett., 68, 101-117.
DOI
|
22 |
Groothuis, F.A., Heringa, M.B., Nicol, B., Hermens, J.L., Blaauboer, B.J. and Kramer, N.I. (2015) Dose metric considerations in in vitro assays to improve quantitative in vitro?in vivo dose extrapolations. Toxicology, 332, 30-40.
DOI
|
23 |
Hinderliter, P.M., Price, P.S., Bartels, M.J., Timchalk, C. and Poet, T.S. (2011) Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos. Regul. Toxicol. Pharmacol., 61, 82-92.
DOI
|
24 |
Kedderis, G.L. (2007) In vitro to in vivo extrapolation of metabolic rate constants for physiologically based pharmacokinetic models. Toxicokinet. Risk Assess., 185-210.
|
25 |
Yoon, M., Kedderis, G.L., Yan, G.Z. and Glewell, H.J. (2015) Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. Toxicology, 332, 52-66.
DOI
|
26 |
Johnson, T.N., Rostami-Hodjegan, A. and Tucker, G.T. (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. pharmacokinet., 45, 931-956.
DOI
|
27 |
Nong, A., McCarver, D.G., Hines, R.N. and Krishnan, K. (2006) Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol., 214, 78-87.
DOI
|
28 |
Wetmore, B.A., Allen, B., Clewell, H.J., Parker, T., Wambaugh, J.F., Almond, L.M. and Thomas, R.S. (2014) Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. Toxicol. Sci., 142, 210-224.
DOI
|
29 |
Hines, R.N. (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol. Ther., 118, 250-267.
DOI
|
30 |
Rowland, M., Peck, C. and Tucker, G. (2011) Physiologicallybased pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol., 51, 45-73.
DOI
|
31 |
Sheets, L.P., Doherty, J.D., Law, M.W., Reiter, L.W. and Crofton, K.M. (1994) Age-dependent differences in the susceptibility of rats to deltamethrin. Toxicol. Appl. Pharmacol., 126, 186-190.
DOI
|
32 |
Anand, S.S., Kim, K.B., Padilla, S., Muralidhara, S., Kim, H.J., Fisher, J.W. and Bruckner, J.V. (2006) Ontogeny of hepatic and plasma metabolism of deltamethrin in vitro: role in age-dependent acute neurotoxicity. Drug Metab. Dispos., 34, 389-397.
|
33 |
Kim, K.B., Anand, S.S., Kim, H.J., White, C.A., Fisher, J.W., Tornero-Velez, R. and Bruckner, J.V. (2010) Age-, dose-and time-ependency of plasma and tissue distribution of deltamethrin in immature rats. Toxicol. Sci., 115, 354-368.
DOI
|
34 |
Crow, J.A., Borazjani, A., Potter, P.M. and Ross, M.K. (2007) Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol. Appl. Pharmacol., 221, 1-12.
DOI
|
35 |
Godin, S.J., Scollon, E.J., Hughes, M.F., Potter, P.M., DeVito, M.J. and Ross, M.K. (2006) Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats. Drug Metab. Dispos., 34, 1764-1771.
DOI
|
36 |
Hideo, K. (2012) Biotransformation and enzymes responsible for metabolism of pyrethroids in mammals, in parameters for pesticide QSAR and PBPK/PD models for human risk assessment. Am. Chem. Soc., 41-52.
|
37 |
Ross, M.K., Borazjani, A., Edwards, C.C. and Potter, P.M. (2006) Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. Biochem. Pharmacol., 71, 657-669.
DOI
|
38 |
Clewell, H.J. and Yoon, M. (2015) Predicting pyrethroids target tissue exposure across ages: application of in vitro-in vivo extrapolation and physiologically based pharmacokinetic modeling. EPA-HQ-OPP-2015-0130.
|
39 |
Hines, R.N. (2007) Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol., 21, 169-175.
DOI
|
40 |
Yang, D., Pearce, R.E., Wang, X., Gaedigk, R., Wan, Y.J. and Yan, B. (2009) Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol., 77, 238-247.
DOI
|
41 |
Mirfazaelian, A., Kim, K.B., Anand, S.S., Kim, H.J., Tornero-Velez, R., Bruckner, J.V. and Fisher, J.W. (2006) Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. Toxicol. Sci., 93, 432-442.
DOI
|
42 |
Tornero-Velez, R., Mirfazaelian, A., Kim, K.B., Anand, S.S., Kim, H.J., Haines, W.T., Bruckner, J.V. and Fisher, J.W. (2010) Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. Toxicol. Appl Pharmacol., 244, 208-217.
DOI
|
43 |
Lake, B.G. (2015) Studies on the in vitro metabolism of deltamethrin by rat and human tissue preparations. EPA-HQOPP-2015-0130.
|
44 |
Pope, C.N., Karanth, S., Liu, J. and Yan, B. (2005) Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. Regul. Toxicol. Pharmacol., 42, 64-69.
DOI
|